<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Ischemic stroke in children: Management and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Ischemic stroke in children: Management and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Ischemic stroke in children: Management and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christine Fox, MD, MAS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sabrina E Smith, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Scott E Kasner, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas R Nordli, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 05, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         While more common in older adults, stroke also occurs in neonates, infants, children, and young adults, resulting in significant morbidity and mortality.
        </p>
        <p>
         An overview of the management and prognosis of arterial ischemic stroke in children one month of age or older is provided here. Other aspects of ischemic stroke in children and neonates are reviewed elsewhere:
        </p>
        <p>
         <a class="medical medical_review" href="/z/d/html/6213.html" rel="external">
          Ischemic stroke in children and young adults: Epidemiology, etiology, and risk factors
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">
          Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/107995.html" rel="external">
          Hemorrhagic stroke in children
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/6157.html" rel="external">
          Stroke in the newborn: Classification, manifestations, and diagnosis
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/114253.html" rel="external">
          Stroke in the newborn: Management and prognosis
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/1103.html" rel="external">
          Cerebral venous thrombosis: Etiology, clinical features, and diagnosis
         </a>
         <br/>
         <a class="medical medical_review" href="/z/d/html/1109.html" rel="external">
          Cerebral venous thrombosis: Treatment and prognosis
         </a>
        </p>
        <p class="headingAnchor" id="H2836868204">
         <span class="h1">
          INITIAL MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         No randomized controlled trials of treatment in acute childhood stroke have been performed. In general, treatment of pediatric stroke is largely adapted from treatment of adult stroke. However, the treatment of children with stroke diverges from that of adults regarding the use of acute anticoagulation and the use of reperfusion therapies (intravenous thrombolysis and mechanical thrombectomy).
        </p>
        <p>
         Our management recommendations for pediatric stroke are based on the clinical experience of experts, recommendations from consensus guidelines [
         <a href="#rid1">
          1-3
         </a>
         ], clinical trials in adults, and the clinical experience of the authors.
        </p>
        <p class="headingAnchor" id="H3725469256">
         <span class="h2">
          Intensive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with acute stroke are best managed initially in an intensive care unit, preferably one with experience in managing pediatric stroke [
         <a href="#rid3">
          3
         </a>
         ]. For most children with suspected acute arterial ischemic stroke, the following supportive measures are recommended  (
         <a class="graphic graphic_algorithm graphicRef103189" href="/z/d/graphic/103189.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintain airway, breathing, and circulation (ABCs). Aspiration precautions include initial nil per os (NPO, nothing by mouth) restriction until swallowing function is evaluated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintain normoglycemia; persistent hyperglycemia is associated with worse outcomes. Therefore, it is reasonable to treat hyperglycemia, when present, to keep blood glucose levels between 140 and 180 mg/dL while avoiding hypoglycemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintain normothermia; identify and treat sources of fever (temperature &gt;38°C) and use antipyretic medications to lower temperature in patients with fever.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Start normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         intravenously at maintenance rate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allow modest hypertension; hypotension should be corrected aggressively with measures including intravenous fluids, keeping the head of bed flat, and use of pressors if needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform frequent neurologic checks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Begin respiratory and oxygen saturation monitoring, along with oxygen supplementation as needed to keep oxygen saturation &gt;95 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Utilize cardiac monitoring for the first 24 hours after stroke onset to look for atrial fibrillation or other potentially serious cardiac arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Start venous thromboembolism prophylaxis with pneumatic compression device for patients restricted to bed with paralysis or diminished consciousness. (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Approach to VTE prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Most children with acute ischemic stroke should be positioned as flat as possible in bed for at least the first 24 hours from stroke onset because of the high frequency of large vessel arteriopathies in childhood stroke, ideally with head-of-bed elevation kept close to 0 degrees, but 30 degrees if there is concern for nausea and vomiting. However, exacerbation of cerebral edema or elevated intracranial pressure (ICP) may occur with flat head-of-bed positioning. Significant aggravation of elevated ICP is unlikely in the first 24 hours after ischemic stroke onset but can occur after 24 hours. Thus, patients with large ischemic infarction of unknown onset or more than 24 hours since onset should be maintained at 30 degrees in bed, once hypovolemia and large vessel arteriopathies have been excluded.
        </p>
        <p class="headingAnchor" id="H3635968256">
         <span class="h2">
          Reperfusion with thrombolysis and thrombectomy
         </span>
        </p>
        <p class="headingAnchor" id="H2746061613">
         <span class="h3">
          Approach to reperfusion in children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recognizing that safety and efficacy data are lacking in patients younger than 18 years of age (see
         <a class="local">
          'Experience in children'
         </a>
         below), acute reperfusion therapies with intravenous thrombolysis and/or mechanical thrombectomy (where available at experienced centers) may be appropriate for selected children with arterial ischemic stroke. In all cases, decisions regarding reperfusion therapies should be made in consultation with neurologists who have expertise in the treatment of children with stroke [
         <a href="#rid3">
          3,5,6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous thrombolysis
         </strong>
         – In view of case reports of good outcomes in children when following adult guidelines, evidence that the risk of symptomatic intracranial hemorrhage after tPA is low when given to children within 4.5 hours of symptom onset [
         <a href="#rid7">
          7
         </a>
         ], and the obstacles to performance of clinical trials in children with this relatively uncommon clinical scenario, it is reasonable to offer intravenous thrombolysis with
         <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">
          alteplase
         </a>
         (recombinant tissue-type plasminogen activator, tPA) for adolescents (age ≥13 years) who otherwise fit eligibility criteria used for adults  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. However, intravenous alteplase is not approved in the United States by the US Food and Drug Administration for use in children less than 18 years of age with ischemic stroke. Although the use of
         <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">
          tenecteplase
         </a>
         is increasing for intravenous thrombolysis in adult stroke, there are few data regarding its safety or dosing in pediatric stroke [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Strict adherence to the accepted time limits and other eligibility criteria used in adults should be observed if thrombolytic therapy is employed for adolescents or children. Many pediatric stroke centers employ a higher threshold for offering intravenous thrombolysis in children compared with the adult guidelines, and include vascular imaging as part of hyperacute stroke imaging protocols to determine the presence of a vascular occlusion prior to offering treatment [
         <a href="#rid9">
          9-11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In order to exclude stroke mimics, we consider intravenous thrombolysis for older children (eg, ≥13 years of age) with confirmed arterial ischemic stroke (eg, as demonstrated by restricted diffusion on magnetic resonance imaging [MRI]) who have a persistent disabling neurologic deficit and evidence of partial or complete arterial occlusion on magnetic resonance (MR) angiography or computed tomography (CT) angiography in the territory of the ischemic stroke [
         <a href="#rid3">
          3,12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115775.html" rel="external">
          "Approach to reperfusion therapy for acute ischemic stroke"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest
         <strong>
          not
         </strong>
         using intravenous tPA for younger children (age &lt;2 years) with stroke [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanical thrombectomy
         </strong>
         – In general accord with a 2019 consensus statement from the American Heart Association/American Stroke Association, we suggest consideration of mechanical thrombectomy for children when the following criteria apply [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children with an acute ischemic stroke on neuroimaging (eg, as demonstrated by restricted diffusion on MRI or a large vessel occlusion on CT angiography in a child with a clinical stroke syndrome) who meet the time limits and other eligibility criteria used in adults  (
         <a class="graphic graphic_algorithm graphicRef141874" href="/z/d/graphic/141874.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A persistent disabling neurologic deficit, with a Pediatric National Institute of Health Stroke Scale  (
         <a class="graphic graphic_table graphicRef76120" href="/z/d/graphic/76120.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef83406" href="/z/d/graphic/83406.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef83405" href="/z/d/graphic/83405.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef83404" href="/z/d/graphic/83404.html" rel="external">
          figure 3
         </a>
         ) score ≥6 at the time of intervention  (
         <a class="graphic graphic_algorithm graphicRef141874" href="/z/d/graphic/141874.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A cerebral large artery occlusion confirmed by MR angiography or CT angiography in the territory of the ischemic stroke.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Small children may incur higher risks from thrombectomy compared with larger children due to the challenges associated with introducing catheters into small groin and cerebral arteries and size-based limitations on contrast dye and radiation exposure [
         <a href="#rid3">
          3
         </a>
         ]. High-quality evidence to define the minimum size or age for the use of mechanical thrombectomy is lacking, but available data suggest that thrombectomy can be safe and beneficial even in small children when performed by experienced stroke neurointerventional radiologists. In a retrospective analysis of registry data from the Save ChildS cohort study, there were 73 children ranging in age from 0.7 to 18 years with acute arterial ischemic stroke who had endovascular recanalization with aspiration or stent retriever devices [
         <a href="#rid13">
          13
         </a>
         ]. Stent retriever size was not associated with rates of recanalization, complications, or with outcomes, and there was no difference in these measures comparing use of first-pass aspiration with other endovascular methods (mainly stent retrievers). Overall neurologic outcomes were good while complication rates were low and did not differ between age groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thrombectomy should be done by an interventionalist with experience both in treating children and in performing thrombectomy for adult patients with stroke [
         <a href="#rid3">
          3,5
         </a>
         ]. Clinical experience with treating children is particularly important when deciding whether younger or smaller children may safely undergo thrombectomy, and when choosing catheters, radiation exposure, and use of intravenous contrast.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3090480873">
         <span class="h3">
          Experience in children
         </span>
         <span class="headingEndMark">
          —
         </span>
         In adults, randomized controlled trials have established that intravenous thrombolytic therapy with
         <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">
          alteplase
         </a>
         improves functional outcome at three to six months when given within 4.5 hours of ischemic stroke onset for eligible patients, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/115775.html" rel="external">
          "Approach to reperfusion therapy for acute ischemic stroke", section on 'Alteplase'
         </a>
         .)
        </p>
        <p>
         Similarly, there is compelling evidence from randomized controlled trials that early mechanical thrombectomy is effective for reducing disability in selected adult patients with acute ischemic stroke. (See
         <a class="medical medical_review" href="/z/d/html/115663.html" rel="external">
          "Mechanical thrombectomy for acute ischemic stroke"
         </a>
         .)
        </p>
        <p>
         By contrast, there is only limited evidence regarding the use of these therapies for children. There are retrospective reports [
         <a href="#rid14">
          14-21
         </a>
         ] and registry data [
         <a href="#rid22">
          22-26
         </a>
         ] of intravenous or intra-arterial thrombolysis use in small numbers of children with acute arterial ischemic stroke. However, the effectiveness, safety and dose of
         <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">
          alteplase
         </a>
         for the treatment of children with arterial ischemic stroke have not been established [
         <a href="#rid27">
          27
         </a>
         ]. Likewise, mechanical thrombectomy in children has not been rigorously tested, but limited observational data suggest safety when done by neuro-interventional radiologists with pediatric experience and careful selection of patients [
         <a href="#rid5">
          5,13,28-33
         </a>
         ]. Safety of mechanical thrombectomy in children with inflammatory arteriopathy, moyamoya vasculopathy, or dissection is uncertain.
        </p>
        <p>
         Efforts to investigate thrombolysis and endovascular therapies for acute ischemic stroke in children have faced daunting obstacles. As an example, Thrombolysis in Pediatric Stroke (TIPS), the first multicenter prospective treatment trial in acute pediatric stroke, aimed to determine safety, dosing, and feasibility of intravenous tPA in children, but was closed in 2013 for lack of accrual [
         <a href="#rid34">
          34
         </a>
         ]. Despite the obstacles, experts in the pediatric stroke community recognize the need for establishment of pediatric acute stroke centers and evidence-based guidelines for hyperacute stroke therapy in children [
         <a href="#rid3">
          3,9,10,35,36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H451132808">
         <span class="h2">
          Early antithrombotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most children with acute arterial ischemic stroke, we suggest starting
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         (3 to 5 mg/kg per day, maximum 325 mg daily) as soon as possible within 24 hours of confirming the diagnosis, in the absence of contraindications such as hemorrhagic transformation [
         <a href="#rid1">
          1
         </a>
         ]. However, the approach to acute antithrombotic treatment varies, and some pediatric centers start with anticoagulation [
         <a href="#rid37">
          37
         </a>
         ]. Note that aspirin, other antiplatelet agents, and anticoagulant agents should
         <strong>
          not
         </strong>
         be used for the first 24 hours after treatment with intravenous thrombolysis.
        </p>
        <p>
         In adults with acute ischemic stroke, early initiation of
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         has established efficacy. (See
         <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">
          "Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack", section on 'Efficacy of aspirin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H166755408">
         <span class="h2">
          Seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seizures are a common accompaniment of arterial ischemic stroke in children. In children with stroke and altered mental status, electroencephalographic (EEG) screening or monitoring can be useful to evaluate for subclinical seizures [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">
          "Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'Clinical presentation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6218.html" rel="external">
          "Seizures and epilepsy in children: Clinical and laboratory diagnosis"
         </a>
         .)
        </p>
        <p>
         In the absence of acute seizures or a history of epilepsy, seizure prophylaxis is not indicated. For children who present with one or more seizures, antiseizure medication therapy (eg,
         <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">
          levetiracetam
         </a>
         ) during the acute phase of stroke is reasonable. Continuation of antiseizure medications may not be necessary for most children after the acute period (eg, one to two weeks if seizures do not recur), as provoked seizures that occur with illness have a lower risk of recurrence than unprovoked seizures.
        </p>
        <p class="headingAnchor" id="H744620683">
         <span class="h2">
          Cerebral edema
         </span>
         <span class="headingEndMark">
          —
         </span>
         With ischemic stroke, large infarcts are associated with cerebral edema and increased ICP. Signs and symptoms of elevated ICP should be frequently assessed, particularly for children with large infarcts. These include the presence of positional headache, vomiting, irritability or combativeness, declining mental status, sixth nerve palsies, and papilledema. Cushing triad (ie, hypertension, bradycardia, and respiratory depression) is highly suggestive of elevated ICP but is typically a late finding.
        </p>
        <p>
         For any neurologic deterioration, a brain imaging study (MRI or CT) should be obtained promptly to assess for worsening edema or herniation.
        </p>
        <p>
         General measures for children with increased ICP include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid treatment of hypoxia, hypercarbia, and hypotension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevation of the head of the bed to at least 30 degrees
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance of the head and neck midline to facilitate venous drainage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aggressive treatment of fever with antipyretics and cooling blankets
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Control of shivering in intubated patients with muscle relaxants (eg,
         <a class="drug drug_pediatric" data-topicid="12877" href="/z/d/drug information/12877.html" rel="external">
          vecuronium
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12774" href="/z/d/drug information/12774.html" rel="external">
          rocuronium
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance of adequate analgesia to blunt the response to noxious stimuli
        </p>
        <p>
        </p>
        <p>
         Additional medical interventions for management of increased ICP include hyperventilation to partial pressure of carbon dioxide (PCO
         <sub>
          2
         </sub>
         ) of 25 to 30 mmHg (if the child is intubated) and hyperosmolar therapy with intravenous
         <a class="drug drug_pediatric" data-topicid="12570" href="/z/d/drug information/12570.html" rel="external">
          mannitol
         </a>
         (bolus 1 g/kg, given as an intravenous infusion through an in-line filter over 20 to 30 minutes, followed by infusions of 0.25 to 0.5 g/kg as needed, generally every six to eight hours) or hypertonic
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         to promote osmotic diuresis (see
         <a class="medical medical_review" href="/z/d/html/106112.html" rel="external">
          "Elevated intracranial pressure (ICP) in children: Management", section on 'Hyperosmolar therapy'
         </a>
         ). If hyperosmolar therapy is administered, close monitoring of plasma osmoles and electrolytes is required to avoid hypovolemia, hypotension, and renal failure.
        </p>
        <p>
         Ultimately, these medical interventions are only temporizing measures, and decompressive craniectomy may be necessary to control refractory elevations in ICP and/or mass effect.
        </p>
        <p class="headingAnchor" id="H2010022088">
         <span class="h2">
          Malignant cerebral edema and herniation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebral infarction
         </strong>
         – Children with acute infarction affecting the middle cerebral artery territory are at risk for developing malignant hemispheric infarction, which is a syndrome characterized by space-occupying cerebral edema leading to brain herniation. Medical interventions for cerebral edema (see
         <a class="local">
          'Cerebral edema'
         </a>
         above) have only a temporary effect, and decompressive craniectomy may be necessary to control refractory elevations in ICP and/or mass effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children with large malignant middle cerebral artery territory stroke associated with mass effect, midline shift, and deterioration of consciousness, we suggest urgent decompressive hemicraniectomy. In this setting, some experts advise either early prophylactic hemicraniectomy within the first 24 hours or serial neuroimaging within the first 72 hours to monitor for swelling and the need for decompressive surgery [
         <a href="#rid3">
          3
         </a>
         ]. Eligibility criteria for adults, provided in the table  (
         <a class="graphic graphic_table graphicRef108328" href="/z/d/graphic/108328.html" rel="external">
          table 3
         </a>
         ), are likely useful for children as well [
         <a href="#rid3">
          3
         </a>
         ]. Published data for this procedure in children are limited but encouraging [
         <a href="#rid38">
          38-40
         </a>
         ]. In the authors' experience, decompressive hemicraniectomy is both lifesaving and associated with good outcome in children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prolonged seizures and more severe stroke deficits may predict the development of the malignant middle cerebral artery territory infarction. In one retrospective report, all children at least two years of age with initial seizures lasting ≥5 minutes in the first 24 hours after stroke onset and a score ≥8 on the Pediatric National Institute of Health Stroke Scale  (
         <a class="graphic graphic_table graphicRef76120" href="/z/d/graphic/76120.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef83404" href="/z/d/graphic/83404.html" rel="external">
          figure 3
         </a>
         and
         <a class="graphic graphic_figure graphicRef83405" href="/z/d/graphic/83405.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef83406" href="/z/d/graphic/83406.html" rel="external">
          figure 1
         </a>
         ) developed malignant middle cerebral artery territory infarction syndrome [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1096.html" rel="external">
          "Malignant cerebral hemispheric infarction with swelling and risk of herniation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In adults undergoing decompressive hemicraniectomy, the best outcomes were achieved when hemicraniectomy was done within 48 hours of stroke onset. (See
         <a class="medical medical_review" href="/z/d/html/1096.html" rel="external">
          "Malignant cerebral hemispheric infarction with swelling and risk of herniation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebellar infarction
         </strong>
         – For children with cerebellar infarction who develop brainstem compression and neurologic deterioration despite maximal medical therapy, suboccipital craniectomy with dural expansion should be performed [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2137532342">
         <span class="h2">
          Identifying the etiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of children with arterial ischemic stroke should screen for the most common causes, including imaging of intracranial and extracranial cerebral arteries, assessment of heart structure and function, hypercoagulable testing, and evaluation of inflammatory markers [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The full evaluation is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">
          "Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3253527853">
         <span class="h1">
          TREATMENT FOR SPECIFIC CAUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no controlled trials or studies examining the effectiveness of specific treatments for different causes of arterial ischemic stroke in children. Thus, all of the recommendations that follow are based mainly upon extrapolation from studies involving adults, the clinical experience of the authors, and recommendations in consensus guidelines [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H847526863">
         <span class="h2">
          Arteriopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with arterial ischemic stroke related to arteriopathy (excluding adenosine deaminase 2 deficiency), we suggest treatment with
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         (3 to 5 mg/kg per day, up to 81 mg daily) rather than anticoagulation. The evaluation for arteriopathy is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">
          "Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'Arteriopathy evaluation'
         </a>
         .)
        </p>
        <p>
         In most cases, antithrombotic therapy (typically
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         ) is continued for two years, which is the time of highest risk for recurrent stroke [
         <a href="#rid43">
          43
         </a>
         ]. However, the optimal duration of antiplatelet therapy is unknown, and treatment must be individualized. Patients with persistent arteriopathy may benefit from longer treatment.
        </p>
        <p>
         Serial neurovascular imaging during the first year of follow-up is critical to monitor for progression among the common subtypes of childhood arteriopathy, including those with extracranial artery dissection, focal cerebral arteriopathy, and moyamoya [
         <a href="#rid3">
          3
         </a>
         ]. When focal cerebral arteriopathy is suspected, we repeat neurovascular imaging three to seven days after initial imaging. In general, for other arteriopathies, we repeat imaging in one to three months after initial imaging and again at 12 months. MR angiography is the preferred method in most cases, since it avoids radiation exposure and contrast dye exposure that accompany CT angiography and conventional digital subtraction angiography.
        </p>
        <p>
         For arterial ischemic stroke caused by an inflammatory arteriopathy, treatment is directed at the underlying condition. We generally use
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         as initial therapy (3 to 5 mg/kg per day, up to 81 mg daily), but some centers treat with aspirin plus glucocorticoids if focal cerebral arteriopathy-inflammatory type (FCA-i) is suspected, particularly if rapidly progressive [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6213.html" rel="external">
          "Ischemic stroke in children and young adults: Epidemiology, etiology, and risk factors", section on 'FCA-inflammatory type (FCA-i)'
         </a>
         .)
        </p>
        <p>
         Long-term immunosuppressive treatment is generally required to treat primary vasculitides (eg, primary angiitis of the central nervous system, polyarteritis nodosa), while antibiotics are the mainstay of treatment for secondary vasculitides caused by infection (eg, bacterial meningitis, HIV infection). An overview of the treatment of vasculitis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6403.html" rel="external">
          "Vasculitis in children: Management overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H186491455">
         <span class="h2">
          Extracranial dissection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with ischemic stroke due to arterial dissection, we suggest treatment with
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         (3 to 5 mg/kg per day) or anticoagulation with
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         or low molecular weight heparin for three to six months after stroke onset, followed by long-term therapy with aspirin. The choice between antiplatelet and anticoagulant therapy should be guided by the clinical experience of the treating physician and by patient values and preferences, comorbid conditions, and tolerance of these agents. (See
         <a class="medical medical_review" href="/z/d/html/16649.html" rel="external">
          "Cerebral and cervical artery dissection: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         As already noted, serial neurovascular imaging during the first year of follow-up is critical to monitor for progression of childhood arteriopathy, including extracranial artery dissection. In most cases, antithrombotic therapy (typically
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         ) is continued for two years [
         <a href="#rid43">
          43
         </a>
         ]. However, patients with persistent arteriopathy may benefit from longer treatment.
        </p>
        <p>
         For patients with dissection of the V3 segment of the vertebral artery who have recurrent ischemic episodes despite antithrombotic treatment, we evaluate with dynamic angiography to look for rotational vertebral artery stenosis or occlusion. (See
         <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">
          "Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'Multiple posterior circulation infarctions'
         </a>
         .)
        </p>
        <p>
         Some experts suggest consideration of surgical intervention (eg, vertebral artery sacrifice) in cases of unilateral vertebral artery involvement, C1-C2 posterior fusion in cases of bilateral involvement, or surgical exploration of the vertebral canal for possible debridement of fibrous tissue in cases of dynamic vertebral artery compression (ie, bow hunter syndrome) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1081182742">
         <span class="h2">
          Moyamoya
         </span>
         <span class="headingEndMark">
          —
         </span>
         Revascularization surgery is suggested for most children and young adult patients with symptomatic moyamoya disease, particularly considering the ineffectiveness of medical treatment. Although supporting evidence is limited and equivocal, long-term therapy with
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         rather than no medical therapy is suggested for children and adults with asymptomatic or symptomatic ischemic moyamoya. These issues are discussed in greater detail elsewhere.
         <em>
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/1112.html" rel="external">
          "Moyamoya disease and moyamoya syndrome: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         In patients with moyamoya associated with other diseases, it is important to look for and treat the underlying condition when possible. The main example is sickle cell disease, where transfusion therapy is effective in primary and secondary stroke prevention. (See
         <a class="medical medical_review" href="/z/d/html/5926.html" rel="external">
          "Acute stroke (ischemic and hemorrhagic) in children and adults with sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H118501055">
         <span class="h2">
          Cardioembolic source
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with a high initial clinical suspicion for cardioembolism as the etiology (such as those with complex congenital heart disease), we suggest short-term anticoagulation with low molecular weight heparin or
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         until vascular imaging and echocardiography are obtained. Anticoagulation should then be stopped, and
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         initiated if no indication (eg, a confirmed cardioembolic source) is identified by these investigations. (See
         <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">
          "Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'Cardiac evaluation'
         </a>
         .)
        </p>
        <p>
         For children with arterial stroke due to a confirmed cardioembolic source, we suggest initial anticoagulation treatment (rather than
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         ). In this setting, we typically use intravenous
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         (goal partial thromboplastin time [PTT] 60 to 85) or subcutaneous low molecular weight heparin (eg,
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         [1 mg/kg dose every 12 hours] to achieve a goal anti-factor Xa level of 0.5 to 1.0 U/mL) for five to seven days, followed by treatment with low molecular weight heparin or
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         for three to six months. In some cases, switching to a direct oral anticoagulant may be an option. Decisions for choice of anticoagulation should be made in conjunction with a hematologist.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          Aspirin
         </a>
         (3 to 5 mg/kg per day) should be given if there is a contraindication to anticoagulation.
        </p>
        <p>
         Since chronic anticoagulation therapy may benefit children at high risk for recurrent cardiogenic embolism, we refer all children with a cardioembolic source other than atrial fibrillation to a pediatric cardiologist for risk assessment and consideration of long-term oral anticoagulation. We suggest long-term therapy with
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         (3 to 5 mg/kg per day) if chronic anticoagulation is not employed.
        </p>
        <p>
         For children with cardioembolic stroke due to atrial fibrillation, we suggest long-term oral anticoagulation treatment using
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         , with an international normalized ratio (INR) goal of 2.5 (acceptable INR range 2 to 3).
        </p>
        <p class="headingAnchor" id="H2613311088">
         <span class="h2">
          Hypercoagulable state
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with arterial stroke due to a confirmed hypercoagulable state (other than sickle cell disease), we suggest initial anticoagulation treatment (rather than
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         ) with intravenous
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         (goal PTT 60 to 85) or subcutaneous low molecular weight heparin (eg,
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         [1 mg/kg dose every 12 hours] to achieve a goal anti-factor Xa level of 0.5 to 1.0 U/mL) for five to seven days, followed by treatment with low molecular weight heparin or
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         for three to six months. In some cases, a direct oral anticoagulant may be an option. As above, the choice of anticoagulation should be made in conjunction with a hematologist. Aspirin is used if there is a contraindication to anticoagulation.
        </p>
        <p>
         For decisions about long-term secondary stroke prevention, we refer children with arterial ischemic stroke and a hypercoagulable state to a pediatric hematologist, since long-term oral anticoagulation may benefit patients who have venous thrombosis, recurrent thrombotic events, or the antiphospholipid syndrome. Because the precise role of prothrombotic states in stroke pathophysiology remains unclear, clinical practice regarding screening for prothrombotic states and subsequent treatment varies by center. We suggest long-term therapy with
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         (3 to 5 mg/kg per day) if long-term anticoagulation is not employed.
        </p>
        <p>
         The evaluation and management of prothrombotic conditions is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">
          "Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'Hypercoagulable evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1360.html" rel="external">
          "Antithrombin deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">
          "Protein C deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1357.html" rel="external">
          "Protein S deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1355.html" rel="external">
          "Factor V Leiden and activated protein C resistance"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">
          "Prothrombin G20210A"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6837.html" rel="external">
          "Overview of homocysteine"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H870112990">
         <span class="h2">
          Sickle cell disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with acute ischemic stroke resulting from sickle cell disease, management issues are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5926.html" rel="external">
          "Acute stroke (ischemic and hemorrhagic) in children and adults with sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">
          "Prevention of stroke (initial or recurrent) in sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3861831946">
         <span class="h2">
          Deficiency of adenosine deaminase 2
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with deficiency of adenosine deaminase 2 (DADA2), no proven treatment is available. Antithrombotic treatment should be stopped, given susceptibility to hemorrhagic stroke and hemorrhagic transformation of ischemic stroke. Limited data suggest that treatment with tumor necrosis factor inhibitors (
         <a class="drug drug_pediatric" data-topicid="13284" href="/z/d/drug information/13284.html" rel="external">
          etanercept
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="129934" href="/z/d/drug information/129934.html" rel="external">
          golimumab
         </a>
         ) is associated with a reduction in recurrent stroke, but further studies are needed to confirm safety and efficacy [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/132472.html" rel="external">
          "Deficiency of adenosine deaminase 2 (DADA2)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3917646950">
         <span class="h2">
          Unknown etiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although data are limited and consensus opinions conflicting, we suggest
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         3 to 5 mg/kg per day rather than anticoagulation as initial therapy for most children with acute arterial ischemic stroke of unknown etiology (cryptogenic ischemic stroke). Exceptions to the use of any acute antithrombotic treatment (ie, aspirin or anticoagulation) are children with symptomatic hemorrhagic transformation. Children who are already anticoagulated at the time of ischemic stroke onset should not be treated acutely with aspirin.
        </p>
        <p>
         In most cases, antithrombotic therapy (typically
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         ) is continued for two years, which is the time of highest risk for recurrent stroke [
         <a href="#rid43">
          43
         </a>
         ]. However, the optimal duration of antiplatelet therapy is unknown, and treatment must be individualized.
        </p>
        <p class="headingAnchor" id="H932864636">
         <span class="h2">
          Patent foramen ovale
         </span>
         <span class="headingEndMark">
          —
         </span>
         In children with cryptogenic ischemic stroke, the presence of a patent foramen ovale (PFO) is of uncertain significance with respect to the stroke etiology or the risk of recurrence, and unlike adults, there are few data to guide management [
         <a href="#rid3">
          3,47
         </a>
         ]. We suggest
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         (3 to 5 mg/kg per day) rather than percutaneous PFO closure or anticoagulation in this setting. An exception is children with acute deep venous thrombosis or other venous thromboembolism, who are generally treated with anticoagulation for at least several months. (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"
         </a>
         .)
        </p>
        <p>
         There is evidence that percutaneous PFO closure is more effective than medical therapy alone for select adults age ≤60 years with an embolic-appearing cryptogenic ischemic stroke (ie, no evident source of stroke despite a comprehensive evaluation). PFO closure may be considered for older children (age ≥16 years) on an individual basis. (See
         <a class="medical medical_review" href="/z/d/html/1100.html" rel="external">
          "Stroke associated with patent foramen ovale (PFO): Evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          RECURRENT ISCHEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent cerebral ischemia, including stroke and transient ischemic attack (TIA), is common after childhood arterial ischemic stroke, particularly in children with arteriopathy. Estimates of stroke recurrence range from approximately 7 to 20 percent over several years of follow-up [
         <a href="#rid43">
          43,48-52
         </a>
         ].
        </p>
        <p>
         One of the largest reports, the multicenter VIPS study, prospectively followed 354 children with arterial ischemic stroke for a median follow-up of two years [
         <a href="#rid43">
          43
         </a>
         ]. The cumulative ischemic stroke recurrence rates at one month and one year were 7 and 12 percent, respectively. Compared with idiopathic arterial ischemic stroke, index stroke with definite arteriopathy (eg, moyamoya, transient cerebral arteriopathy, dissection, or vasculitis) affecting the cervical or cerebral vessels had a significantly increased risk of recurrence (hazard ratio 5, 95% CI 1.8-14). Other reports suggest that recurrence is more common after posterior circulation arterial ischemic stroke in children compared with anterior circulation arterial ischemic stroke [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p>
         In cases of unexplained recurrent ischemic stroke or TIA, it is important to identify the etiology, focusing on known causes with a relatively high risk of recurrence, which includes various types of arteriopathy, cardiogenic embolism, and hypercoagulable states. (See
         <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">
          "Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'Evaluation for etiology'
         </a>
         .)
        </p>
        <p>
         In the setting of recurrent ischemic stroke or TIA in children on
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         therapy, we suggest changing therapy to either
         <a class="drug drug_pediatric" data-topicid="12984" href="/z/d/drug information/12984.html" rel="external">
          clopidogrel
         </a>
         or anticoagulation (with low molecular weight heparin or
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         ). Consensus guidelines make similar recommendations [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H493231751">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1846515817">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         A study of national registry data from the United States reported that in-hospital mortality after arterial ischemic stroke in children ages 30 days to 18 years was approximately 5 percent [
         <a href="#rid23">
          23
         </a>
         ]. Similarly, among 612 children with arterial ischemic stroke in an international database, the mortality rate prior to hospital discharge was 3 percent [
         <a href="#rid37">
          37
         </a>
         ]. In young adults, mortality is approximately 4 to 6 percent in the first year after ischemic stroke [
         <a href="#rid55">
          55,56
         </a>
         ]. Compared with matched controls, long-term mortality in children is increased beyond 20 years after ischemic stroke [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1644922523">
         <span class="h2">
          Disability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the neural plasticity present in children, the majority of children with stroke have persistent disability [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 90 children with ischemic stroke followed for a median duration of three years, disability that interfered with daily life was present in 60 percent, while a good outcome was present in 40 percent [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a report of 67 children with arterial ischemic stroke and follow-up of one year or more, there was no residual disability in 17 patients (25 percent), mild residual disability in 17 patients (25 percent), and severe residual disability in 33 patients (49 percent) [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study of 123 children with ischemic stroke followed for a mean duration of two years, 37 percent were normal, 20 percent had mild deficits, 26 percent had moderate deficits, 16 percent had severe deficits, and 13 percent developed epilepsy [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Social functioning may be impaired after pediatric stroke. In a study of 36 pediatric stroke patients compared with 15 controls with asthma (to control for effects of a hospital admission and chronic illness), children with stroke had poorer adaptive behavior and social functioning despite similar measures of intelligence quotient (IQ) and processing speed. Stroke severity was associated with greater impairment of social adjustment [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Long-term outcomes after ischemic stroke appear to be similar for children and younger adults. A prospective cohort study compared outcomes of 95 subjects who had arterial ischemic stroke in childhood (ages one month to 16 years) with 154 subjects who had stroke in young adulthood (ages 16 to 45 years) [
         <a href="#rid63">
          63
         </a>
         ]. At a median follow-up of 6.9 years, there were no significant differences between the groups for mortality, disability, or quality of life.
        </p>
        <p class="headingAnchor" id="H2535221036">
         <span class="h2">
          Epilepsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epilepsy appears to be a long-term risk for neonates and children who have had a stroke [
         <a href="#rid64">
          64-66
         </a>
         ]. Epilepsy is common and may be a predictor of lower quality of life. In the population-based Kaiser Pediatric Stroke Study, the cumulative risk of epilepsy was 13 percent by five years and 30 percent by 10 years after a childhood stroke [
         <a href="#rid64">
          64
         </a>
         ]. In a study of 59 patients with perinatal or childhood stroke, those who developed epilepsy had lower scores on quality of life measures compared with children with stroke who did not develop epilepsy [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1773196663">
         <span class="h2">
          Predictors of poor outcome
         </span>
         <span class="headingEndMark">
          —
         </span>
         In various reports of children with ischemic stroke, predictors of poor outcome have included the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Young age [
         <a href="#rid60">
          60,67
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age between 28 days and one year [
         <a href="#rid68">
          68
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large infarct size [
         <a href="#rid67">
          67,69,70
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered consciousness at presentation [
         <a href="#rid37">
          37,71,72
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures at onset [
         <a href="#rid73">
          73
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever at presentation [
         <a href="#rid60">
          60
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Right middle cerebral artery territory infarction [
         <a href="#rid60">
          60
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral ischemia [
         <a href="#rid37">
          37
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arteriopathy [
         <a href="#rid37">
          37,74
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperglycemia during the acute phase [
         <a href="#rid70">
          70
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe persisting deficit one year after stroke onset predicted poor outcome in adulthood [
         <a href="#rid75">
          75
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         In an observational study of 29 children with unilateral stroke in the middle cerebral artery territory, abnormal signal in the descending corticospinal tract (DCST) was seen on diffusion weighted magnetic resonance imaging (MRI) in 20 (69 percent) within two weeks of stroke onset, and correlated with poor motor outcome [
         <a href="#rid76">
          76
         </a>
         ]. In seven children with poor motor outcome, the abnormal DCST signal was either contralateral to the acute stroke or was bilateral, an unexpected and unexplained finding.
        </p>
        <p class="headingAnchor" id="H2849043550">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112685.html" rel="external">
          "Society guideline links: Stroke in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early management
         </strong>
         – Children with suspected acute arterial ischemic stroke are best managed in an intensive care setting with supportive care measures. (See
         <a class="local">
          'Intensive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute reperfusion
         </strong>
         – Acute reperfusion therapies with intravenous thrombolysis and/or mechanical thrombectomy (where available at experienced centers) may be appropriate in selected children with confirmed arterial ischemic stroke. Decisions regarding reperfusion therapies should be made in consultation with neurologists who have expertise in the treatment of children with stroke. (See
         <a class="local">
          'Reperfusion with thrombolysis and thrombectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Early
         </strong>
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         – For most children with acute arterial ischemic stroke, we suggest starting aspirin as soon as possible within 24 hours of confirming the diagnosis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, aspirin and antithrombotic agents should
         <strong>
          not
         </strong>
         be used for the first 24 hours after treatment with intravenous thrombolysis. (See
         <a class="local">
          'Early antithrombotic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring for seizures
         </strong>
         – Seizures may accompany arterial ischemic stroke in children. In children with stroke and altered mental status, electroencephalographic (EEG) screening or monitoring can be useful to evaluate for subclinical seizures. In the absence of acute seizures or a history of epilepsy, seizure prophylaxis is not indicated. (See
         <a class="local">
          'Seizures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Large infarcts
         </strong>
         – Children with large infarcts should be monitored for signs and symptoms of symptomatic cerebral edema and elevated intracranial pressure (ICP). For any neurologic deterioration, a brain imaging study (magnetic resonance imaging [MRI] or computed tomography [CT]) should be obtained promptly to assess for worsening edema or herniation. Medical interventions for management of symptomatic cerebral edema and increased ICP are reviewed in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef110947" href="/z/d/graphic/110947.html" rel="external">
          algorithm 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For children with large malignant middle cerebral artery territory stroke associated with mass effect, midline shift, and deterioration of consciousness, we suggest urgent decompressive hemicraniectomy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Cerebral edema'
         </a>
         above and
         <a class="local">
          'Malignant cerebral edema and herniation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment for specific causes
         </strong>
         – Antithrombotic therapy varies according to stroke mechanism.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Arteriopathy
         </strong>
         – For most children with arterial ischemic stroke related to arteriopathy (excluding deficiency of adenosine deaminase 2), we suggest treatment with
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         (3 to 5 mg/kg per day) rather than anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For inflammatory arteriopathy, treatment is directed at the underlying condition; we generally use aspirin as initial therapy, but some centers treat with aspirin plus glucocorticoids and
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         if focal cerebral arteriopathy-inflammatory type (FCA-i) is suspected, particularly if rapidly progressive. (See
         <a class="local">
          'Arteriopathy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dissection
         </strong>
         – For extracranial arterial dissection, initial treatment with either
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         or anticoagulation (
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         or low molecular weight heparin) is reasonable. (See
         <a class="local">
          'Extracranial dissection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Moyamoya
         </strong>
         – For moyamoya, revascularization surgery is the mainstay of treatment. (See
         <a class="local">
          'Moyamoya'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1112.html" rel="external">
          "Moyamoya disease and moyamoya syndrome: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardiogenic embolism or hypercoagulable state
         </strong>
         – For children with arterial ischemic stroke due to a confirmed cardioembolic source or hypercoagulable state (other than sickle cell disease), we suggest anticoagulation treatment with intravenous
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         or subcutaneous low molecular weight heparin for five to seven days rather than
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         , followed by treatment with low molecular weight heparin or
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          warfarin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Aspirin (3 to 5 mg/kg per day) should be given if there is a contraindication to anticoagulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We refer children with cardioembolic stroke to a pediatric cardiologist, and children with hypercoagulable source to a pediatric hematologist for discussion of long-term anticoagulation. (See
         <a class="local">
          'Cardioembolic source'
         </a>
         above and
         <a class="local">
          'Hypercoagulable state'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sickle cell disease
         </strong>
         – Management is reviewed separately for children with ischemic stroke from sickle cell disease. (See
         <a class="medical medical_review" href="/z/d/html/5926.html" rel="external">
          "Acute stroke (ischemic and hemorrhagic) in children and adults with sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">
          "Prevention of stroke (initial or recurrent) in sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unknown etiology
         </strong>
         – For most children with acute arterial ischemic stroke of unknown etiology, we suggest
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          aspirin
         </a>
         3 to 5 mg/kg per day rather than anticoagulation as initial therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Unknown etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – Recurrent cerebral ischemia affects up to 20 percent of children after childhood arterial ischemic stroke. In cases of unexplained recurrent ischemic stroke or transient ischemic attack (TIA), it is important to identify the etiology, focusing on known causes with a relatively high risk of recurrence, which include various types of arteriopathy, cardiogenic embolism, and hypercoagulable states. (See
         <a class="local">
          'Recurrent ischemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Despite the neural plasticity present in children, the majority of children with stroke have persistent disability. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Stroke in childhood: Clinical guideline for diagnosis, management and rehabilitation (2017). Royal College of Paediatrics and Child Health. http://www.rcpch.ac.uk/stroke-guideline (Accessed on April 18, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferriero DM, Fullerton HJ, Bernard TJ, et al. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke 2019; 50:e51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elbers J, Wainwright MS, Amlie-Lefond C. The Pediatric Stroke Code: Early Management of the Child with Stroke. J Pediatr 2015; 167:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry M, Hallam DK, Bernard TJ, Amlie-Lefond C. What is the Role of Mechanical Thrombectomy in Childhood Stroke? Pediatr Neurol 2019; 95:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chabrier S, Ozanne A, Naggara O, et al. Hyperacute Recanalization Strategies and Childhood Stroke in the Evidence Age. Stroke 2021; 52:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amlie-Lefond C, Shaw DWW, Cooper A, et al. Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children. Stroke 2020; 51:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun LR, Wilson JL, Waak M, et al. Tenecteplase in Acute Stroke: What About the Children? Stroke 2023; 54:1950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivkin MJ, Bernard TJ, Dowling MM, Amlie-Lefond C. Guidelines for Urgent Management of Stroke in Children. Pediatr Neurol 2016; 56:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernard TJ, Friedman NR, Stence NV, et al. Preparing for a "Pediatric Stroke Alert". Pediatr Neurol 2016; 56:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalaf A, Iv M, Fullerton H, Wintermark M. Pediatric Stroke Imaging. Pediatr Neurol 2018; 86:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amlie-Lefond C, Chan AK, Kirton A, et al. Thrombolysis in acute childhood stroke: design and challenges of the thrombolysis in pediatric stroke clinical trial. Neuroepidemiology 2009; 32:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sporns PB, Straeter R, Minnerup J, et al. Does Device Selection Impact Recanalization Rate and Neurological Outcome?: An Analysis of the Save ChildS Study. Stroke 2020; 51:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thirumalai SS, Shubin RA. Successful treatment for stroke in a child using recombinant tissue plasminogen activator. J Child Neurol 2000; 15:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson MD, Leber S, Deveikis J, Silverstein FS. Successful use of rt-PA in pediatric stroke. Neurology 2001; 57:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirton A, Wong JH, Mah J, et al. Successful endovascular therapy for acute basilar thrombosis in an adolescent. Pediatrics 2003; 112:e248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortiz GA, Koch S, Wallace DM, Lopez-Alberola R. Successful intravenous thrombolysis for acute stroke in a child. J Child Neurol 2007; 22:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan M, Armstrong D, Birken C, et al. Bacterial endocarditis in a child presenting with acute arterial ischemic stroke: should thrombolytic therapy be absolutely contraindicated? Dev Med Child Neurol 2009; 51:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janmaat M, Gravendeel JP, Uyttenboogaart M, et al. Local intra-arterial thrombolysis in a 4-year-old male with vertebrobasilar artery thrombosis. Dev Med Child Neurol 2009; 51:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold M, Steinlin M, Baumann A, et al. Thrombolysis in childhood stroke: report of 2 cases and review of the literature. Stroke 2009; 40:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rambaud T, Legris N, Bejot Y, et al. Acute ischemic stroke in adolescents. Neurology 2020; 94:e158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alshekhlee A, Geller T, Mehta S, et al. Thrombolysis for children with acute ischemic stroke: a perspective from the kids' inpatient database. Pediatr Neurol 2013; 49:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr DM, Biller J, Rabinstein AA. Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients. Pediatr Neurol 2014; 51:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson JL, Eriksson CO, Williams CN. Endovascular Therapy in Pediatric Stroke: Utilization, Patient Characteristics, and Outcomes. Pediatr Neurol 2017; 69:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amlie-Lefond C, deVeber G, Chan AK, et al. Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study. Lancet Neurol 2009; 8:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur N, Patel S, Ayanbadejo MO, et al. Age-specific trends in intravenous thrombolysis and mechanical thrombectomy utilization in acute ischemic stroke in children under age 18. Int J Stroke 2023; 18:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016; 47:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sporns PB, Sträter R, Minnerup J, et al. Feasibility, Safety, and Outcome of Endovascular Recanalization in Childhood Stroke: The Save ChildS Study. JAMA Neurol 2020; 77:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cobb MIH, Laarakker AS, Gonzalez LF, et al. Endovascular Therapies for Acute Ischemic Stroke in Children. Stroke 2017; 48:2026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sporns PB, Psychogios MN, Straeter R, et al. Clinical Diffusion Mismatch to Select Pediatric Patients for Embolectomy 6 to 24 Hours After Stroke: An Analysis of the Save ChildS Study. Neurology 2021; 96:e343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dicpinigaitis AJ, Gandhi CD, Pisapia J, et al. Endovascular Thrombectomy for Pediatric Acute Ischemic Stroke. Stroke 2022; 53:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilgin C, Ibrahim M, Azzam AY, et al. Mechanical Thrombectomy for Pediatric Large Vessel Occlusions : A Systematic Review and Meta-analysis. Clin Neuroradiol 2023; 33:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatia KD, Chowdhury S, Andrews I, et al. Association Between Thrombectomy and Functional Outcomes in Pediatric Patients With Acute Ischemic Stroke From Large Vessel Occlusion. JAMA Neurol 2023; 80:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivkin MJ, deVeber G, Ichord RN, et al. Thrombolysis in pediatric stroke study. Stroke 2015; 46:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernard TJ, Rivkin MJ, Scholz K, et al. Emergence of the primary pediatric stroke center: impact of the thrombolysis in pediatric stroke trial. Stroke 2014; 45:2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauzier DC, Galardi MM, Guilliams KP, et al. Pediatric Thrombectomy: Design and Workflow Lessons From Two Experienced Centers. Stroke 2021; 52:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg NA, Bernard TJ, Fullerton HJ, et al. Antithrombotic treatments, outcomes, and prognostic factors in acute childhood-onset arterial ischaemic stroke: a multicentre, observational, cohort study. Lancet Neurol 2009; 8:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramaswamy V, Mehta V, Bauman M, et al. Decompressive hemicraniectomy in children with severe ischemic stroke and life-threatening cerebral edema. J Child Neurol 2008; 23:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SE, Kirkham FJ, Deveber G, et al. Outcome following decompressive craniectomy for malignant middle cerebral artery infarction in children. Dev Med Child Neurol 2011; 53:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehman LL, DeVeber G, Pergami P, et al. Characteristics and Outcome in Children With Craniectomy Following Acute Ischemic Stroke in the International Pediatric Stroke Study. J Child Neurol 2019; 34:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade A, Bigi S, Laughlin S, et al. Association Between Prolonged Seizures and Malignant Middle Cerebral Artery Infarction in Children With Acute Ischemic Stroke. Pediatr Neurol 2016; 64:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijdicks EF, Sheth KN, Carter BS, et al. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fullerton HJ, Wintermark M, Hills NK, et al. Risk of Recurrent Arterial Ischemic Stroke in Childhood: A Prospective International Study. Stroke 2016; 47:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinlin M, Bigi S, Stojanovski B, et al. Focal Cerebral Arteriopathy: Do Steroids Improve Outcome? Stroke 2017; 48:2375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinlin M, O'callaghan F, Mackay MT. Planning interventional trials in childhood arterial ischaemic stroke using a Delphi consensus process. Dev Med Child Neurol 2017; 59:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ombrello AK, Qin J, Hoffmann PM, et al. Treatment Strategies for Deficiency of Adenosine Deaminase 2. N Engl J Med 2019; 380:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. Circulation 2013; 128:2622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sträter R, Becker S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood--a 5-year follow-up study. Lancet 2002; 360:1540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganesan V, Prengler M, Wade A, Kirkham FJ. Clinical and radiological recurrence after childhood arterial ischemic stroke. Circulation 2006; 114:2170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fullerton HJ, Wu YW, Sidney S, Johnston SC. Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging. Pediatrics 2007; 119:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           deVeber GA, Kirton A, Booth FA, et al. Epidemiology and Outcomes of Arterial Ischemic Stroke in Children: The Canadian Pediatric Ischemic Stroke Registry. Pediatr Neurol 2017; 69:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stacey A, Toolis C, Ganesan V. Rates and Risk Factors for Arterial Ischemic Stroke Recurrence in Children. Stroke 2018; 49:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uohara MY, Beslow LA, Billinghurst L, et al. Incidence of Recurrence in Posterior Circulation Childhood Arterial Ischemic Stroke. JAMA Neurol 2017; 74:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goeggel Simonetti B, Rafay MF, Chung M, et al. Comparative study of posterior and anterior circulation stroke in childhood: Results from the International Pediatric Stroke Study. Neurology 2020; 94:e337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marini C, Totaro R, Carolei A. Long-term prognosis of cerebral ischemia in young adults. National Research Council Study Group on Stroke in the Young. Stroke 1999; 30:2320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leys D, Bandu L, Hénon H, et al. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology 2002; 59:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundelin HEK, Walås A, Söderling J, et al. Long-Term Mortality in Children With Ischemic Stroke: A Nationwide Register-Based Cohort Study. Stroke 2022; 53:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenham M, Gordon A, Anderson V, Mackay MT. Outcome in Childhood Stroke. Stroke 2016; 47:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganesan V, Hogan A, Shack N, et al. Outcome after ischaemic stroke in childhood. Dev Med Child Neurol 2000; 42:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cnossen MH, Aarsen FK, Akker SLj, et al. Paediatric arterial ischaemic stroke: functional outcome and risk factors. Dev Med Child Neurol 2010; 52:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           deVeber GA, MacGregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 2000; 15:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo W, Gordon A, Hajek C, et al. Social competence following neonatal and childhood stroke. Int J Stroke 2014; 9:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goeggel Simonetti B, Cavelti A, Arnold M, et al. Long-term outcome after arterial ischemic stroke in children and young adults. Neurology 2015; 84:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox CK, Glass HC, Sidney S, et al. Acute seizures predict epilepsy after childhood stroke. Ann Neurol 2013; 74:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SE, Vargas G, Cucchiara AJ, et al. Hemiparesis and epilepsy are associated with worse reported health status following unilateral stroke in children. Pediatr Neurol 2015; 52:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundelin HEK, Tomson T, Zelano J, et al. Pediatric Ischemic Stroke and Epilepsy: A Nationwide Cohort Study. Stroke 2021; 52:3532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang B, Hills NK, Forsyth R, et al. Imaging Predictors of Neurologic Outcome After Pediatric Arterial Ischemic Stroke. Stroke 2021; 52:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felling RJ, Rafay MF, Bernard TJ, et al. Predicting Recovery and Outcome after Pediatric Stroke: Results from the International Pediatric Stroke Study. Ann Neurol 2020; 87:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganesan V, Ng V, Chong WK, et al. Lesion volume, lesion location, and outcome after middle cerebral artery territory stroke. Arch Dis Child 1999; 81:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grelli KN, Gindville MC, Walker CH, Jordan LC. Association of Blood Pressure, Blood Glucose, and Temperature With Neurological Outcome After Childhood Stroke. JAMA Neurol 2016; 73:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keidan I, Shahar E, Barzilay Z, et al. Predictors of outcome of stroke in infants and children based on clinical data and radiologic correlates. Acta Paediatr 1994; 83:762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delsing BJ, Catsman-Berrevoets CE, Appel IM. Early prognostic indicators of outcome in ischemic childhood stroke. Pediatr Neurol 2001; 24:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallick AA, Ganesan V, Kirkham FJ, et al. Outcome and recurrence one year after paediatric arterial ischaemic stroke in a population-based cohort. Ann Neurol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg NA, Jenkins S, Jack J, et al. Arteriopathy, D-dimer, and risk of poor neurologic outcome in childhood-onset arterial ischemic stroke. J Pediatr 2013; 162:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elbers J, deVeber G, Pontigon AM, Moharir M. Long-term outcomes of pediatric ischemic stroke in adulthood. J Child Neurol 2014; 29:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domi T, deVeber G, Shroff M, et al. Corticospinal tract pre-wallerian degeneration: a novel outcome predictor for pediatric stroke on acute MRI. Stroke 2009; 40:780.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6215 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://www.rcpch.ac.uk/stroke-guideline" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Stroke in childhood: Clinical guideline for diagnosis, management and rehabilitation (2017). Royal College of Paediatrics and Child Health. http://www.rcpch.ac.uk/stroke-guideline (Accessed on April 18, 2019).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315277" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30686119" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25937428" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The Pediatric Stroke Code: Early Management of the Child with Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30795888" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : What is the Role of Mechanical Thrombectomy in Childhood Stroke?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33349018" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hyperacute Recanalization Strategies and Childhood Stroke in the Evidence Age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31842706" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37226774" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Tenecteplase in Acute Stroke: What About the Children?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26969237" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Guidelines for Urgent Management of Stroke in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26969238" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Preparing for a "Pediatric Stroke Alert".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30122281" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pediatric Stroke Imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19223687" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Thrombolysis in acute childhood stroke: design and challenges of the thrombolysis in pediatric stroke clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32114927" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Does Device Selection Impact Recanalization Rate and Neurological Outcome?: An Analysis of the Save ChildS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10961797" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Successful treatment for stroke in a child using recombinant tissue plasminogen activator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11445651" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Successful use of rt-PA in pediatric stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12949321" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Successful endovascular therapy for acute basilar thrombosis in an adolescent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17641263" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Successful intravenous thrombolysis for acute stroke in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191846" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bacterial endocarditis in a child presenting with acute arterial ischemic stroke: should thrombolytic therapy be absolutely contraindicated?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191847" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Local intra-arterial thrombolysis in a 4-year-old male with vertebrobasilar artery thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118242" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Thrombolysis in childhood stroke: report of 2 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31831601" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Acute ischemic stroke in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24139532" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Thrombolysis for children with acute ischemic stroke: a perspective from the kids' inpatient database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25194722" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28233666" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Endovascular Therapy in Pediatric Stroke: Utilization, Patient Characteristics, and Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19423401" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36250237" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Age-specific trends in intravenous thrombolysis and mechanical thrombectomy utilization in acute ischemic stroke in children under age 18.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26696642" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31609380" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Feasibility, Safety, and Outcome of Endovascular Recanalization in Childhood Stroke: The Save ChildS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28596450" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Endovascular Therapies for Acute Ischemic Stroke in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33144517" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical Diffusion Mismatch to Select Pediatric Patients for Embolectomy 6 to 24 Hours After Stroke: An Analysis of the Save ChildS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35272483" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Endovascular Thrombectomy for Pediatric Acute Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36592199" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mechanical Thrombectomy for Pediatric Large Vessel Occlusions : A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37486670" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Association Between Thrombectomy and Functional Outcomes in Pediatric Patients With Acute Ischemic Stroke From Large Vessel Occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25613306" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Thrombolysis in pediatric stroke study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24916908" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Emergence of the primary pediatric stroke center: impact of the thrombolysis in pediatric stroke trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33691502" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pediatric Thrombectomy: Design and Workflow Lessons From Two Experienced Centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19801204" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Antithrombotic treatments, outcomes, and prognostic factors in acute childhood-onset arterial ischaemic stroke: a multicentre, observational, cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18403586" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Decompressive hemicraniectomy in children with severe ischemic stroke and life-threatening cerebral edema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20804513" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Outcome following decompressive craniectomy for malignant middle cerebral artery infarction in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31282248" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Characteristics and Outcome in Children With Craniectomy Following Acute Ischemic Stroke in the International Pediatric Stroke Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27663488" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Association Between Prolonged Seizures and Malignant Middle Cerebral Artery Infarction in Children With Acute Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24481970" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26556824" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Risk of Recurrent Arterial Ischemic Stroke in Childhood: A Prospective International Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28733481" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Focal Cerebral Arteriopathy: Do Steroids Improve Outcome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28121022" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Planning interventional trials in childhood arterial ischaemic stroke using a Delphi consensus process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30995379" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment Strategies for Deficiency of Adenosine Deaminase 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24226806" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12443591" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prospective assessment of risk factors for recurrent stroke during childhood--a 5-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17075014" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Clinical and radiological recurrence after childhood arterial ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17332202" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28254555" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Epidemiology and Outcomes of Arterial Ischemic Stroke in Children: The Canadian Pediatric Ischemic Stroke Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29540607" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Rates and Risk Factors for Arterial Ischemic Stroke Recurrence in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28114639" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Incidence of Recurrence in Posterior Circulation Childhood Arterial Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31857436" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Comparative study of posterior and anterior circulation stroke in childhood: Results from the International Pediatric Stroke Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10548665" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Long-term prognosis of cerebral ischemia in young adults. National Research Council Study Group on Stroke in the Young.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12105303" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34875844" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Long-Term Mortality in Children With Ischemic Stroke: A Nationwide Register-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26956257" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Outcome in Childhood Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10972417" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Outcome after ischaemic stroke in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20089051" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Paediatric arterial ischaemic stroke: functional outcome and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10830198" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25388858" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Social competence following neonatal and childhood stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25862797" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Long-term outcome after arterial ischemic stroke in children and young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23613472" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Acute seizures predict epilepsy after childhood stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25559938" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hemiparesis and epilepsy are associated with worse reported health status following unilateral stroke in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34470493" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pediatric Ischemic Stroke and Epilepsy: A Nationwide Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33280552" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Imaging Predictors of Neurologic Outcome After Pediatric Arterial Ischemic Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32215969" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Predicting Recovery and Outcome after Pediatric Stroke: Results from the International Pediatric Stroke Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10490431" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Lesion volume, lesion location, and outcome after middle cerebral artery territory stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27214847" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Association of Blood Pressure, Blood Glucose, and Temperature With Neurological Outcome After Childhood Stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7949809" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Predictors of outcome of stroke in infants and children based on clinical data and radiologic correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11377103" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Early prognostic indicators of outcome in ischemic childhood stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26928665" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Outcome and recurrence one year after paediatric arterial ischaemic stroke in a population-based cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23260102" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Arteriopathy, D-dimer, and risk of poor neurologic outcome in childhood-onset arterial ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23589374" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Long-term outcomes of pediatric ischemic stroke in adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19131656" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Corticospinal tract pre-wallerian degeneration: a novel outcome predictor for pediatric stroke on acute MRI.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
